Author Archives: Lu Rahman

#Antibodies #Biologics / Biotechnology #Therapeutics

Just-Evotec Biologics gets grant for antibody product for the prevention of COVID-19

Evotec’s Seattle-based subsidiary, Just–Evotec Biologics has received a grant from the Bill & Melinda Gates Foundation as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody (mAb) candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries. Under… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Electronic Lab Notebooks (ELN)

New functionality added to Thermo Scientific SampleManager LIMS software

In response to the data management needs of manufacturing QA/QC and contract laboratories, the latest version of Thermo Scientific’s SampleManager Laboratory Information Management System (LIMS) software offers an advanced solution: a built-in electronic lab notebook (ELN), capabilities to streamline operations within contract laboratories and enhanced dashboard configuration for tailored data… Read More

#News

#Antibodies #Clinical trials #Covid-19

NIH study aims to identify promising COVID-19 treatments for larger clinical trials

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials. The ACTIV-5 Big Effect Trial,… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #CNS #Drug discovery

Collaboration seeks innovative treatments for CNS disorders

Blue Oak Pharmaceuticals, an innovator in the discovery of transformative CNS drugs, and Exscientia, a clinical-stage Artificial Intelligence (AI) drug-discovery company, have announced an innovative drug-discovery collaboration to treat brain disorders. This collaboration combines Blue Oak’s therapeutic area expertise and ability to design novel, CNS focused privileged chemotypes with Exscientia’s… Read More

#News

#Drug development #Drug discovery

Human models for human drug development

By FRAME (Fund for the Replacement of Animals in Medical Experiments) CEO, Celean Camp, FRAME Alternatives Laboratory Director, Dr Andrew Bennett and FRAME Scientific Liaison Officer, Amy Beale. Animals remain the first choice for testing and research in drug discovery and development, despite scientific advances across a range of… Read More

#Opinion

#Assays #Biologics / Biotechnology #Drug discovery

Axol Bioscience: multi-electrode array screening for human iPSC-derived cells 

Axol Bioscience, a biotechnology company specialising in the use of stem cell technology to manufacture disease-relevant cell-based assay systems to the drug discovery industry, has introduced multi-electrode array (MEA) screening for human induced pluripotent stem cell (hiPSC)-derived cells. The new services have been developed to support pre-clinical research by optimising hiPSC-derived… Read More

#News

#AI / data analytics / healthtech / informatics

Talking Medicines to scale up AI pharma tool

Data tech innovator Talking Medicines, which uses advanced AI to provide pharmaceutical companies with real-time data intelligence, has been chosen to join Tech Nation’s Applied AI 2.0 Growth Programme. Tech Nation’s growth programmes are designed to champion and support ‘the UK’s most exceptional deep tech scaleups’ and alumni include Skyscanner,… Read More

#News

#Antibodies #Biologics / Biotechnology #Biopharma

Bristol Myers Squibb licences IONTAS’ mammalian display technology

IONTAS, a biotechnology company focused on antibody discovery technology development, has entered into a licensing agreement with Bristol Myers Squibb regarding its proprietary mammalian display. Under the terms of this agreement, IONTAS will receive an upfront payment for accessing the technology platform and will work with Bristol Myers Squibb in… Read More

#News

#Cell therapy

New platform identifies epigenetic switches driving cell identity and cell maintenance

Mogrify’s EpiMOGRIFY platform models the epigenetic state of the cell to predict the switches important for cell identity, cell maintenance, directed differentiation and cell conversion. EpiMOGRIFY is an extension of the company’s proprietary direct cellular conversion technology, MOGRIFY, and enables the identification of the optimal culture conditions required to maintain cells… Read More

#News

#Cold chain #Covid-19 #Immunology / Virology & Vaccines

Keeping the cold chain unbroken for COVID research and vaccine development

Robin Vacha, Senior Vice President, Products at Brooks Life Sciences and David Lewandowski, Global Business Development Manager, Cryo Division at Brooks Life Sciences examine the role of unbroken cold chain in research and development As COVID-19 vaccine research continues to grow at an unparalleled pace, so does the need for… Read More

#Covid-19 #Exclusive Content

#CAR-T #T-Cells

Flow cytometry in immuno-oncology: tools to evaluate potential drugs

Researchers are continually looking for processes and technology that give them the edge scientifically or commercially. If you are a biotech scientist interested in reversing or overcoming the state of T-cell exhaustion, this webinar will be beneficial to your work. Quantifying T cell exhaustion: An insight into BiTE antibodies… Read More

#News

#AI / data analytics / healthtech / informatics #Flow Cytometry

Automated flow cytometry analysis tools unlock pharma research insights

Tariq E. Khoyratty DPhil, Computational Biologist, Aigenpulse, and Satnam Surae PhD, Chief Product Officer, Aigenpulse, discuss the challenge of the large volume of data generated and how automation/AI/ML can help to manage this. As pharmaceutical companies expand their research and development (R&D) efforts to meet the growing global demand for new drugs,… Read More

#Exclusive Content

#Marketing approval authorisation #Pharmacovigilance #Regulatory

Pharmacovigilance audits: implications of poor pass rates for drug developers

Vanessa Fachada Oliveira, Pharmacovigilance Manager & EU QPPV at Arriello, discusses 10 common issues identified in risk-based audits, and pinpoints implications for drug developers as well as marketing authorisation holders (MAHs). In EU markets, pharmacovigilance (PV) provisions are closely monitored to ensure that patients can have maximum confidence in the safety… Read More

#Exclusive Content #Regulatory

#Cell and Gene Therapy Catapult #Cell therapy #Gene therapy

High potential opportunity zone named for cell and gene therapy

The UK Department for International Trade (DIT) has classified Stevenage in the UK, as a High Potential Opportunity (HPO) zone in recognition of its thriving cell and gene therapy cluster of national and international significance. The successful HPO nomination was made by Hertfordshire Local Enterprise Partnership (LEP) and is expected… Read More

#News

#AI / data analytics / healthtech / informatics

Rhythm AI receives MHRA approval for ROCSTAR clinical trial

Rhythm AI, a UK company focused on the treatment of Atrial Fibrillation (AF) has received approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with its multi-centre ROCSTAR clinical trial. This program will assess the company’s STAR Mapping System as a potential treatment for persistent AF. Read More

#News